Streetbeat News

Equity Actions

DIS

Blackwells Capital criticizes Nelson Peltz's candidacy for Disney's board, advocating instead for their own nominees Jessica Schell, Craig Hatkoff, and Leah Solivan. They encourage Disney shareholders to vote using the Green Proxy Card.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:33 am

BTAI

BioXcel Therapeutics' stock price is trading lower following the announcement of a $25 million registered direct offering.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:23 am

MASI

Politan Capital Management, holding an 8.9% stake in Masimo, has nominated two independent candidates, Darlene Solomon and William Jellison, for election to the Masimo Board.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:13 am

CMMB

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) has been granted a new European patent for CM-101, its monoclonal antibody in Phase 2 clinical development for treating primary sclerosing cholangitis. The patent strengthens Chemomab's intellectual property for CM-101, which targets CCL24, a key player in fibrosis and inflammation. The global Phase 2 SPRING trial for CM-101 has completed patient enrollment, with results expected by mid-2024.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:09 am

BTAI

BioXcel Therapeutics, Inc. (BTAI) announced a registered direct offering of over 3 million shares and warrants, plus pre-funded warrants for approximately $25 million in aggregate gross proceeds. The offering includes common stock and warrants at a price of $2.901 per share and warrant, and pre-funded warrants at $2.900 per share, with an exercise price of $0.001 for pre-funded warrants and $3.20 for accompanying warrants.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:03 am

UTHR

United Therapeutics Corporation (UTHR) has announced a new accelerated share repurchase program, authorizing the repurchase of up to $1 billion of its common stock. This initiative complements the company's ongoing financial strategy, which includes a planned $400 million paydown of its revolving credit facility in 2024, with $100 million already paid down in the first quarter.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 11:02 am

NKTX

Nkarta's stock is trading higher following the announcement of a $240 million underwritten offering.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 10:45 am

NKTX

Nkarta has announced the pricing of its underwritten offering of 21 million shares at $10.00 per share and pre-funded warrants to purchase 3 million shares at $9.9999 per warrant, aiming to raise approximately $240.1 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 10:34 am

SGMT

Sagimet Biosciences reported a FY EPS of $(2.66), which may not be comparable to the $(25.91) estimate. The company's sales were $2.00K. It anticipates a cash runway through 2025, following a follow-on offering in January 2024 for $104.7M, and reported cash, cash equivalents, and marketable securities of $94.9M.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 10:19 am

NVO

Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, including upfront and milestone payments. Cardior specializes in RNA-targeted therapies for heart diseases, with its lead compound CDR132L in phase 2 for heart failure treatment. This acquisition aims to enhance Novo Nordisk's cardiovascular disease pipeline.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 10:06 am